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SHORT-TERM OUTCOMES AND LONG-TERM PROGNOSIS OF ORAL CAVITY 
CANCER. Zachary G. Schwam, Benjamin L. Judson (advisor). Section of 
Otolaryngology, Department of Surgery, Yale University School of Medicine, New 
Haven, CT. 
We sought to characterize short-term morbidity and mortality outcomes as well as 
long-term changes in prognosis for oral cancer patients. We predicted that clinical and 
demographic variables would affect short- and long-term outcomes. Retrospective 
analyses of the National Surgical Quality Improvement Program (NSQIP) and National 
Cancer Database (NCDB) were performed on 408 and 13,655 patients, respectively. Chi-
square, Kaplan Meier, logistic regression, and Cox proportional hazards regression were 
performed. In the NSQIP, the overall adverse event and mortality rates were 20.3% and 
1.0%, respectively. The most common complications were reoperation, infection, and 
respiratory complications. Over 90% of post-discharge complications occurred by post-
discharge day (PDD) 14, but the majority of surgical-site infections and dehiscences 
occurred by PDD 7. Neck dissection, smoking, and weight loss were associated with 
several complications in multivariate analysis. In the NCDB, three-year overall survival 
increased by 36.2% and 16.0% for patients with early and late stage disease (LSD), 
respectively. In LSD patients, adjuvant chemoradiotherapy increased from 8.3% to 36.4%. 
Later year of diagnosis (hazard ratio [HR] 0.76), neck dissection (HR 0.90), and negative 
margins (HR 1.00) were associated with better overall survival (all p≤.002). Many 
patients with oral cavity cancers experience postoperative complications, some of which 
occur post-discharge. Early follow-up should be sought for high-risk patients. Long-term 
prognosis for oral cancers has increased dramatically, as has the administration of 
adjuvant chemoradiotherapy in LSD. Numerous sociodemographic, clinical, and 
treatment variables may account for this difference in survival.  
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Introduction  
Sub-sites and lymphatic drainage patterns of the oral cavity 
 The oral cavity is composed of seven sub-sites, namely the lip, oral tongue, 
alveolar ridge, retromolar trigone, floor of mouth, buccal mucosa, and hard palate (3).  
While the anatomy and lymphatic drainage of the oral cavity is varied and complex, some 
patterns have emerged in terms of sites of nodal metastases from oral cancers.  In a 
review of 1,081 patients at Memorial Sloan Kettering Cancer Center undergoing radical 
neck dissections between 1965 and 1986, 562 neck dissections were performed for oral 
cavity malignancies (4).  In those patients, lymph node metastases were found to 
predominate in cervical lymph node levels I, II, and III, and were rarely found in levels 
IV or V.  “Skip lesions” were also not observed, in that any patients with level V nodal 
metastases also had metastases in levels I-IV.    
 
Epidemiology of oral cancer 
It is estimated that 59,340 new primary cancers of the head and neck were 
diagnosed in the United States in 2015, with 12,290 associated deaths (5). Primary 
tumors of the oral cavity were estimated to cause over 30,000 of those cases (51%) and 
nearly 6,000 (49%) deaths. Oral cavity cancer is also common worldwide, and is the 
fifteenth most common malignancy according to the World Health Organization (6). Oral 
cancers are more common in men, which is thought to be secondary to higher rates of 
tobacco and alcohol use, as well as greater exposure to sunlight via outdoor occupations 
in the case of lip cancer (7). Oral cancer is predominantly a disease of middle age, with 
only 6% of cases reported in patients under 45 years of age (8). The median age at 
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diagnosis in the United States was 62.0 years between years 2000 and 2004 (6,9), 
although there are reports of an increasing incidence of oral tongue squamous cell 
carcinoma in young white males aged 20-44 years (10).  
 
Risk factors for developing oral cavity squamous cell carcinoma  
Risk factors for the development of oral cavity cancer have been well-
characterized, and overlap with those of many of the other head and neck sub-sites. 
Tobacco and alcohol use have been associated with the development of many head and 
neck cancers, and have been estimated to cause nearly three-quarters of oral cavity cancer 
cases (11).  Tobacco is found in many forms, with cultural differences in its consumption 
related to distinct anatomic locations of lesions within the oral cavity.  Dipping snuff is 
common in the Southern United States, and has been associated with a 50-fold higher 
incidence of buccal and gingival lesions (12).  Similarly, the large percentage of the 
population in Bombay, India that chews pan, a tobacco derivative, contributes to very 
high rates of buccal cancers (13).  Additionally, hard palate carcinomas are particularly 
common amongst Indian women who engage in “reverse chutta smoking,” in which the 
lit end of a cigar is placed inside the mouth (14). Smoking cigarettes, pipes, and cigars 
have also linked to the development of oral cavity cancers, with pipe and cigar smokers at 
higher risk of developing oral cancers than cigarette smokers (15). Tobacco products all 
exhibit a dose-response tumorigenic effect (16), with polycyclic aromatic hydrocarbons 
(PAHs), nicotine-derived nitrosamine ketones (NNKs), and N-nitrosonornicotine (NNN) 
creating DNA adducts in addition to oxidative damage by nitric oxide and quinones (17).  
Tobacco use is not only linked to development of head and neck squamous cell 
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carcinomas, but is also associated with more aggressive disease; patients with a history of 
tobacco use are more likely to have regional metastases and extracapsular spread when 
compared to those without such a history (18).       
 
Worldwide, 3.6% of cancers are related to alcohol consumption, notably the oral 
cavity, pharynx, larynx, liver, breast, esophagus, and colon (19).  Ethanol consumption 
has been observed to have a dose-response effect, with a progressively higher relative 
risk of developing oral cancer with increasing ethanol intake.  In certain case-control 
studies, drinking ≥6 whiskey-equivalents daily had a higher relative risk than did 
smoking ≥40 cigarettes daily on the development of oral carcinomas (20).  While the 
exact mechanism behind ethanol’s association is as of yet unknown, it is thought to 
behave synergistically with tobacco through a direct topical effect (13,21).  Mechanisms 
proposed include mucosal exposure to high concentrations of acetaldehyde, a breakdown 
product of ethanol generated by oral bacteria (19,22) that interferes with DNA synthesis 
and repair by binding to enzymes involved in cytosine methylation and glutathione 
production (19,23,24).  Acetaldehyde also binds to DNA, forming mutagenic adducts 
(25). Oral acetaldehyde concentrations have been found to be higher in smokers, with the 
theory that smoking somehow shifts the native flora to more acetaldehyde-producing 
species (26).  Cigarette smoke itself has also been found to have rather high 
concentrations of acetaldehyde.  
 
Cancers of the lip have a distinct epidemiological pattern when compared to those 
of the oral cavity, with additional risk factors including exposure to sunlight, pipe 
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smoking, fair complexion (27), and immunosuppression (28).  Pipe smoking is thought to 
cause lip cancer through multiple mechanisms, including mechanical irritation, thermal 
injury, and chemical exposure (3,29).  In Australia, Canada, and Spain, lip cancer is the 
most common sub-site of the oral cavity (30). It is important to distinguish cancers of the 
lip from surrounding sub-sites, notably the buccal mucosa and adjacent skin.   
 
Additional risk factors for cancer of the oral cavity include poor dental hygiene, 
(specifically not brushing one’s teeth every day) and wearing ill-fitting dentures that have 
caused sores (31).  While the effects of poor dentition can be measured, they tend to be 
greatly outweighed by the effects of tobacco and alcohol (32).  
 
Histology common to oral cancers 
 In an analysis of the National Cancer Database (NCDB) examining 58,976 
patients with oral cancer, the most common subtypes were found to be squamous cell 
carcinoma (86.3%), adenocarcinoma (5.6%), and verrucous carcinoma (2.0%). The 
remaining were split evenly by carcinoma not otherwise specified, lymphoma, Kaposi 
sarcoma, and “other” (33).   
 
 While conventional squamous cell carcinoma is the most common subtype, 
multiple variants can be found within the oral cavity, including sarcomatoid, basaloid, 
and verrucous squamous cell carcinoma (3). Sarcomatoid squamous cell carcinoma stains 
positively for keratin, has squamous cells intermingling with spindle-type cells, and has a 
similar overall survival to that of conventional squamous cell carcinoma. There is, 
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however, a higher rate of locoregional recurrence (34).  Basaloid squamous cell 
carcinomas typically have basaloid cells, prominent peripheral nuclear palisading (35), 
and have a predilection for the oral tongue (36). Basaloid lesions tend to have similar 
survival curves to moderate to poorly differentiated squamous cell carcinomas (36).  In 
verrucous lesions, which are commonly found on the buccal mucosa, there is typically a 
thick zone of non-proliferating and non-keratinizing cells.  It is considered low-grade in 
nature and resistant to radiation (3). Numerous additional pathologies of the oral cavity 
may be found, including minor salivary gland tumors, melanoma, sarcomas (including 
Kaposi’s sarcoma), lymphoma, and granulomas.   
 
Treatment options and factors affecting treatment 
The treatment of oral cavity (including lip) cancers is guided by clinical and 
pathological staging information, presence of high-risk pathologic features, and success 
of surgical resection.  Surgical resection of the primary is the backbone of treatment, with 
elective or therapeutic neck dissection based on presence of clinically positive nodes, 
tumor thickness, or the results of sentinel lymph node biopsy.  Adjuvant radiotherapy can 
be considered in the case of having one positive node without having adverse features, 
but is indicated and frequently combined with chemotherapy if there is extracapsular 
extension, positive margins, or other adverse features such as pathologic T3/T4 
classification, N2/N3 nodal disease, nodal disease in levels IV or V, as well as perineural 
and lymphovascular invasion.  Definitive radiotherapy is also an option in the case of 
small lesions without nodal metastases, with salvage surgery reserved for recurrence (37).  
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 Presence of nodal metastasis is an important prognostic factor in oral cancers; as a 
result, there has been much effort to determine predictors of occult nodal metastases in 
the clinically negative neck (38,39), with rates of occult nodal metastases in T1/T2 
lesions as high as 27-40% (40,41,42). Tumor thickness is thought to reflect proximity to 
lymphatic and vascular structures (43) and to approximate aggressiveness of tumor 
growth (44).  It has also been postulated that tumor emboli are more apt to spread along 
the wider lymphatic channels located in the deeper aspects of the tissue (45).  Tumor 
thickness ≥4mm is considered to be an indication for elective neck dissection, as 4.5% of 
patients are expected to have occult metastases with a thickness of 4mm, while 16.6% 
have them with a cutoff of 5mm (46).  A recent randomized control trial of node-negative 
oral cancer patients demonstrated a superior overall and disease-free survival for patients 
undergoing elective as compared to therapeutic neck dissection (47).  
 
Reconstruction after oncologic resection 
 For small lesions of the oral cavity, primary closure, placement of a split-
thickness skin graft, or healing by secondary intention may be considered.  Larger lesions 
may require free-tissue transfer or a regional pedicle flap, and are dependent on surgeon 
preference and ability as well as patient expectations (3).    
 
Effects of disease and treatment on quality of life 
The oral cavity is an integral anatomic region, playing important roles in speech, 
deglutition, taste, salivation, and mastication.  As a result, tumor-induced dysfunction as 
well as treatment-related effects may have a profound impact on a patient’s day-to-day 
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functioning.  Numerous factors have been found to affect quality of life in oral cavity 
cancer patients, including the site of tumor, tumor size, depressive symptoms, pre-
operative performance status, method of reconstruction, and whether a patient underwent 
neck dissection (48).  While there have been articles reporting no effect of tumor site on 
quality of life, it has also been demonstrated that more posterior tumors may have a 
profound effect based on the impact on deglutition (49).  Similarly, larger tumors and 
overall stage are often associated with worse pain and physical symptoms, especially 
when treated with multimodality therapy (48, 50). Anxiety and depression are prevalent 
among those with oral cancers (51), and disfigurement often leads to changes in self-
perception, isolation, and problems with partners (52).  
 
Much attention has been paid to the effect of surgical reconstruction on quality of 
life, with some authors reporting that primary closure and laser surgery have superior 
outcomes to free-flap reconstruction one year post-operatively (48,49).  In a prospective 
trial examining quality of life after free tissue transfer for oropharyngeal cancer 
reconstruction, an initial decline in performance was observed, but recovered by 6 
months. Mental health and emotional indices were superior to pre-treatment levels at one 
year post-operatively (53).  No differences in quality of life measures have been noted in 
post-maxillectomy patients undergoing reconstruction with a free flap versus obturator 
(54), or for bony free flap versus marginal mandibulectomy in resection of large 
mandibular tumors (55).  Extent of neck dissection has also been related to postoperative 
shoulder dysfunction and pain, most notably in patients undergoing bilateral neck 
dissections of levels I-IV or any dissection including level V (56).   
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Synchronous and metachronous tumors 
Patients with head and neck squamous cell carcinomas have or develop a second 
primary in 10-40% of cases, with common sites including the head and neck, esophagus, 
and lung (57). Synchronous lesions are those that are diagnosed within 6 months of the 
initial cancer, and metachronous lesions occur after the 6-month window has passed. 
Panendoscopy of the upper aerodigestive tract and the tracheobronchial tree at the time of 
diagnosis routinely yields a second primary tumor in 9-14% of cases (58,59). Up to 33% 
of patients with oral cavity primaries have been found to have second primaries, with 
most being found in the oral cavity, pharynx, larynx, lung, and esophagus (58). The risk 
of developing a second oral cancer is highest in patients with primaries of the gingiva, 
floor of mouth, and buccal mucosa, with gingival and floor of mouth primaries most 
likely to have their second lesions in the lung (60,61,62). Identification of a second 
primary was linked to a substantial decrease in five-year overall survival from 26.9% to 
15.2% in one series (63).  
 
Role of adjuvant therapy in treating oral cancer 
Before 2004, locoregionally advanced head and neck squamous cell carcinoma 
was typically treated with surgical resection and adjuvant radiotherapy. With this 
treatment algorithm, rates of locoregional recurrence, distant metastasis, and five-year 
overall survival rates were 30%, 25%, and 40%, respectively (64,65). The Radiation 
Therapy Oncology Group (RTOG) 9501 and European Organization for Research and 
Treatment of Cancer (EORTC) 22931 trials, which were both published in 2004, showed 
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a significant improvement in disease-free survival and locoregional control for high-risk 
and late stage head and neck cancer patients. The two trials, however, had discordant 
results with respect to overall survival, with EORTC 22931 showing a significant 
improvement, and RTOG 9501 only demonstrating minimal improvement (2,66,67). 
While different end-outcomes and definitions of “high risk” were used, a combined 
follow-up analysis demonstrated the greatest benefit of adjuvant chemoradiotherapy to be 
in those with positive margins or ECE (2,65).     
 
Effect of screening in oral cancer 
 Currently, the United States Preventive Services Task Force maintains that there 
is insufficient evidence for routine oral cancer screening in asymptomatic adults (68). 
While routine oral cancer screening has not gained traction in the United States, there has 
been some success on an international level.  In a longitudinal screening program in 
Kerala, India, nearly 200,000 people were randomized to either undergo serial visual 
screenings or be placed in a control group over a thirteen-year period.  While a reduction 
of 12% in oral cancer mortality did not reach significance when all patients were 
combined, tobacco/alcohol users in the serial screening group had a 38% lower incidence 
of oral cancer and 81% lower oral cancer mortality when compared to patients in the 
control group (69).  Other efforts have focused on salivary biomarker detection in high-
risk patients (70), as well as autofluorescence visualization devices, cytological brush 
tests (71), and differential gene expression using microarrays (72).   
 
Current literature on short term outcomes and long term prognosis 
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 The five-year relative survival rates for many head and neck cancers have 
improved over the years, with increases from 53% (1975-77) to 66% (2004-10) for oral 
cavity and pharyngeal primaries (5). This is in contrast to laryngeal primaries, which 
have seen a significant decrease in their five-year relative survival from 66% to 63% over 
the same period.  This may be due to roughly two-thirds of head and neck cancer patients 
presenting with advanced disease (73), and between 4-25% eventually developing distant 
metastases. It has been found that between 7% and 12% have distant metastases at 
presentation (73,74,75).  Even in light of advances in diagnostic imaging and methods 
and increased awareness, the proportion of head and neck cancer patients presenting with 
Stage IV disease has not changed appreciably since 1990 (76).  
  
 Data on changes in prognosis of oral cavity malignancies are varied, with some 
reports stating that the five-year survival rate has remained relatively stable over several 
decades at 50-55%, with variations based on several variables including race and gender 
(77,78,79).  Oral cavity sub-site has also been shown to have prognostic value, with 
cancers of the oral tongue showing a worse overall and cause-specific survival when 
compared to other oral sub-sites (80).  The long-term prognosis for lip cancer, however, 
is excellent, with five-year survival rates of 95% (77,79).  These data are in contrast to an 
international cohort study from seven leading cancer centers that demonstrated a 
significant improvement in survival for oral cancer patients (81), and a report from 
Memorial Sloan Kettering Cancer Center showing a significant increase in survival for 
oral tongue cancers between 1978 and 1987 (82).     
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 Unfortunately, postoperative complications are rather common in head and neck 
cancer patients, with reported complication rates as high as 53% (83,84,85,86).  Wound 
infections at the surgical site are the most common (85) in the literature, with risk factors 
including neoadjuvant therapy (86), advanced disease (83,84,85), comorbidity, and neck 
dissection (83).  In a retrospective review of 1,693 Taiwanese oral cavity cancer patients 
undergoing primary resection, the wound infection rate was found to be 19.8%, with risk 
factors including diabetes, flap reconstruction, and low postoperative serum albumin 
level (83). Thirty-day readmission and mortality has been reported using the NCDB for 
patients with oral cavity squamous cell carcinoma (87), and Chen et al. have examined 
postdischarge complications for all otolaryngology procedures in the NSQIP (88).  As 
postdischarge complications are one of the most important contributors to readmission 
(89) and may delay the receipt of critical adjuvant therapies, investigating them remains 
critical.  
 
Purpose, aims, and hypotheses 
 The purpose of this study was multifold, and included characterizing both short-
term morbidity and mortality outcomes as well as long-term changes in prognosis for 
patients with cancers of the oral cavity using large administrative datasets. We 
hypothesized that clinical and demographic variables such as age and various 
comorbidities would affect short-term postoperative morbidity and mortality, and sought 
to characterize modifiable risk factors to predict which patient populations were at 
highest risk. It was also our aim to characterize the time course of postoperative and post-
discharge complications (1).  While we anticipated the majority of complications to occur 
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during admission, we believed that certain adverse events would tend to occur after 
discharge. In identifying risk factors for postoperative adverse events, we predicted that 
more preoperative comorbidity would be re associated with more morbidity and mortality 
postoperatively. In investigating the long-term prognosis for patients with oral cavity 
squamous cell carcinoma, we predicted that three-year overall survival would increase 
over the study period, and would likely be associated with the administration of adjuvant 
therapies, superior surgical techniques as measured by rates of negative margins, as well 
as socio-demographic and oncologic variables such as age, cancer stage, and the category 
of treatment center (2).  
  
Methods  
Division of responsibility 
All procedures, methods, and statistical analyses were performed principally by 
the first author.  This included selecting the cohort, choosing inclusion and exclusion 
criteria, recoding and redefining variables, univariate and multivariate analysis, creation 
of tables and figures, and authorship of the manuscript. Data interpretation was chiefly 
performed by the first author with assistance from the faculty advisor.  
 
Description of the National Surgical Quality Improvement Program§ 
To characterize and determine the timing of postoperative complications 
following oncologic resection of oral cavity malignancies, we utilized the American 
                                                        
§Adapted with permissions from: Schwam ZG, Sosa JA, Roman SA, Judson BL. Complications and mortality 
following surgery for oral cavity cancer: analysis of 408 cases. Laryngoscope 2015;125:1869-73. 
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College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) 
Participant Use Data File (PUF) to examine data from patients undergoing surgery 
between 2005 and 2010 (1). The NSQIP collects data from over 400 participating sites, 
and is prospective, risk-adjusted, and validated against claims data in recording major 
postoperative complications (1,90,91). The NSQIP is the only national dataset of its kind. 
Data on 135 variables detailing preoperative patient characteristics and comorbid 
conditions, intraoperative processes, and postoperative morbidity and mortality are 
carefully recorded by a Surgical Clinical Nurse Reviewer at each site, and data are not 
limited to in-hospital events (1,92,93,94). Due to a robust auditing and training process, 
the inter-rater reliability of variables in the database has improved over the years, 
ensuring standardization of data inputs (95).  The NSQIP clinical reviewers rely on an 
eight-day cycle in which representative cases are selected from the operative logs to 
ensure lack of bias in selection; using this process, cases “have an equal chance of being 
selected from each day of the week (96).”      
 
Description of the National Cancer Database† 
The NCDB was used to determine changes in long-term prognosis of patients 
with oral cavity squamous cell carcinoma diagnosed between years 1998-2006. The 
NCDB is a joint venture of the American Cancer Society and the Commission on Cancer 
(CoC) of the American College of Surgeons, and has been in existence since 1989 (2,97).  
It accounts for more than 1440 CoC-approved cancer program registries (2,76,98), 
approximately 75% of cancers diagnosed in the United States, and is the pre-eminent 
                                                        
†Adapted with permissions from Schwam ZG, Judson BL. Improved prognosis for patients with oral cavity squamous 
cell carcinoma: analysis of the National Cancer Database 1998-2006. Oral Oncol 2016;52:45-51. 
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oncologic database in the United States.  The NCDB uses the same definitions and 
standards as federal cancer registry systems (99), with coding guidelines found in the 
Registry Operations and Data Standards (100) and Facility Oncology Registry Data 
Standards manuals (2,101).  Data is collected on socio-demographic, clinical, oncologic, 
and treatment-related variables.  
    
Selection criteria using the ACS NSQIP§ 
The NSQIP was queried by International Classification of Diseases-9th edition 
(ICD-9) codes (102), selecting for malignant lesions of the oral cavity: 141.1-141.5, 
144.0, 144.1, 144.8, 144.9, 145.0-145.2, 145.6, 145.8, and 145.9 (1).  The following 
Current Procedural Terminology (CPT) codes were then included in the analysis either as 
the principal or concurrent procedure: 21025, 21026, 21034, 21040, 21044, 21045, 21050, 
21198, 21299 (bony excision), 21557 (radical tumor resection), 31225 (maxillectomy), 
41116 (excision from floor of mouth), 40810, 40812, 40814, 40816, 40899 (excision 
from vestibule of mouth), 41110, 41112, 41114, 41120, 41130, 41135, 41140, 41145, 
41599 (excision of tongue lesion, glossectomy with or without neck dissection), 41150, 
41153, 41155 (glossectomy as part of composite procedure, with or without neck 
dissection), 41825, 41827, 41830 (excision of dento-alveolar structures), 42104, 42106, 
42107, 42120, 42140, 42160, 42299 (excision or destruction palatal or uvular lesion), 
42415 (excision of parotid tumor), 42842, 42844, and 42845 (radical resection of 
retromolar trigone with or without flap reconstruction) (1,103).  
 
                                                        
§Adapted with permissions from: Schwam ZG, Sosa JA, Roman SA, Judson BL. Complications and mortality 
following surgery for oral cavity cancer: analysis of 408 cases. Laryngoscope 2015;125:1869-73. 
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Preoperative and intraoperative variables in the NSQIP§ 
 Definitions of variables included in the database are described in the ACS-NSQIP 
user guide (104) with several modifications (1).  “Pulmonary comorbidity” was defined 
as having dyspnea on exertion or at rest, a history of chronic obstructive pulmonary 
disease, or being ventilator-dependent.  “Cardiovascular comorbidity” was defined as a 
history of congestive heart failure, angina, myocardial infarction (MI), peripheral 
vascular disease, percutaneous coronary intervention, or cardiac surgery.  “Poor 
functional status” prior to surgery was defined as being either partially or totally 
dependent on others for activities of daily living.  Neck dissection was determined by the 
following CPT codes (1,103): 38542 (dissection of deep jugular nodes), 38700, 41153 
(suprahyoid neck dissection), 38720, 38724, 41135, 41155, and 42426 (includes 
complete lymphadenectomy, modified radical neck dissection, radical neck dissection, or 
neck dissection in addition to another procedure). Cases in which neck dissection was the 
only procedure performed were excluded from analysis (1).   
 
Postoperative outcomes in the NSQIP§ 
Complications and adverse events analyzed included surgical-site (superficial, 
deep, and organ-space, and wound-dehiscence), infectious (urinary tract infection, 
pneumonia, sepsis, and septic shock), respiratory (re-intubation, failure to wean, or 
ventilator use >48 hours), renal (acute renal insufficiency or acute renal failure), and 
cardiovascular complications (myocardial infarction, cardiac arrest, or stroke), as well as 
flap failure, venous thromboembolism (deep venous thrombosis or pulmonary embolism), 
                                                        
§Adapted with permissions from: Schwam ZG, Sosa JA, Roman SA, Judson BL. Complications and mortality 
following surgery for oral cavity cancer: analysis of 408 cases. Laryngoscope 2015;125:1869-73. 
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reoperation, and death (1,105).   
 
Selection Criteria using the NCDB† 
We extracted oral cancer patient data from the NCDB using the following 
International Classification of Diseases for Oncology, 3rd edition (ICD-O-3) (2,106) 
topography codes: C00.0, 00.1, 00.2, 00.3, 00.4, 00.5, 00.6, 00.8, 00.9 (Lip), 02.0, 02.1, 
02.2, 02.3, 02.8, 02.9 (oral tongue), 03.0, 03.1, 03.9 (gingiva and alveolus), 04.0, 04.1, 
04.8, 04.9 (floor of mouth), 05.0, 05.8, 05.9 (hard palate), 06.0, 06.1 (buccal mucosa), 
06.2 (retromolar trigone), 06.8, and 06.9 (other and unspecified mouth).  We then 
selected for patients with squamous cell carcinomas using the following ICD-O-3 
morphology codes 8051, 8052, 8070-8076, 8078, 8083, and 8084 (2,105).  Patients with 
T0, TX, Tis, and NX lesions as well as those with Stage 0 disease were excluded.  
Staging information reflects the American Joint Committee on Cancer (AJCC) staging 
system, 5th (1998-2002) and 6th editions (2003-2006) (107,108).  Patients with incomplete 
information for the following variables of interest were not included in our analyses: 
patient gender, age, race, Hispanic origin, insurance status, facility type, TNM 
classifications and overall stage, information on first course of treatment (surgery, 
chemotherapy, radiation, surgical margins, scope of regional lymph node surgery), last 
contact/death, and vital status at follow-up (2).   
 
Variable definitions in the NCDB† 
                                                        
†Adapted with permissions from Schwam ZG, Judson BL. Improved prognosis for patients with oral cavity squamous 
cell carcinoma: analysis of the National Cancer Database 1998-2006. Oral Oncol 2016;52:45-51.  
†Adapted with permissions from Schwam ZG, Judson BL. Improved prognosis for patients with oral cavity squamous 
cell carcinoma: analysis of the National Cancer Database 1998-2006. Oral Oncol 2016;52:45-51. 
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Variable definitions are as defined in the NCDB data dictionary (109), with some 
exceptions.  Patients were coded as diagnosed in years 1998-2003 or 2004-2006, as the 
landmark RTOG 9501 and EORTC 22931 trials involving the use of adjuvant therapy in 
head and neck cancer were first published in 2004 (2,65,66,67).  Hispanic origin was 
combined with race, and those of Hispanic origin were labeled “Hispanic.”  Insurance 
status was stratified into private, uninsured/Medicaid, and Medicare/other government.  
Facility type was divided into Academic/Research Cancer Programs (ARPs) and non-
ARPs (87).  Facility volume was categorized as high or low, with high-volume centers 
treating ≥22 patients (≥90th percentile) over the study period. All patients underwent 
surgical resection of the primary site, and some received adjuvant radiation or 
chemoradiation.  Surgical margins were characterized as being negative 
(microscopically) or positive (micro- or macroscopically, or unspecified).  Patients who 
underwent regional lymph node surgery were coded as having received a neck dissection 
(87).  High-risk pathologic features such as tumor depth, perineural invasion, and 
extracapsular extension are not available for the vast majority of patients in the database; 
therefore these variables could not be analyzed.  Data regarding Charlson comorbidity 
index was only available for patients diagnosed years 2003-2006, and was therefore not 
examined (2).     
 
Statistical analysis§† 
                                                        
§†Adapted with permissions from:  
Schwam ZG, Judson BL. Improved prognosis for patients with oral cavity squamous cell carcinoma: analysis of the 
National Cancer Database 1998-2006. Oral Oncol 2016;52:45-51. 
Schwam ZG, Sosa JA, Roman SA, Judson BL. Complications and mortality following surgery for oral cavity cancer: 
analysis of 408 cases. Laryngoscope 2015;125:1869-73. 
 
  
18 
Statistical analysis was performed with SPSS version 22.0.0 (Chicago, IL). 
Standard descriptive statistics were used to summarize patient demographic and disease-
related data.  Cases with missing data for variables of interest (<5%) were removed from 
the NSQIP cohort. Extreme outliers were removed in calculating summary statistics if 
values fell three times the interquartile distance from the 75th percentile value. Chi-square, 
Kaplan-Meier, and Cox proportional hazards regression analyses were performed, and 
only variables with p≤.10 in univariate analyses were included in multivariate models.  
All tests were two-sided, and final threshold for significance was set at p≤.05.  Temporal 
trends in the first course of treatment and three-year overall survival were depicted using 
Prism Graphpad 6.0 (La Jolla, CA), and Pearson product-moment correlation coefficients 
were calculated to determine the temporal associations between different treatment 
modalities and overall survival.  Correlation coefficients range from   -1 to +1, which 
represent perfect negative and positive linear correlations, respectively.  This study was 
granted exemption by our institutional review board, as both the NSQIP and NCDB are 
de-identified datasets (1,2).    
 
Results 
Patient demographics and clinical characteristics in the NSQIP  
In querying the NSQIP to identify cases of oral cavity cancer undergoing primary 
resection in addition to other procedures, 408 cases were identified.  The oral tongue 
(40.7%), floor of mouth (21.8%), buccal mucosa (7.1%), retromolar trigone (6.1%), and 
hard palate (4.9%) were the most common oral cavity sub-sites (1).  
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 The majority of patients were male, between the ages of 45-79 years, and 
Caucasian (Table 1).  Many had significant comorbid conditions, including diabetes, 
tobacco use within the year prior to surgery, heavy alcohol use, prior strokes/transient 
ischemic attacks, and hypertension. Few patients received neoadjuvant chemotherapy or 
radiotherapy for their disease.  Steroids for a chronic condition and poor functional status 
prior to surgery were uncommon comorbidities. Weight loss greater than 10% over the 
six months prior to surgery occurred in just under 7% of patients, and 3% of patients had 
a procedure performed within the 30 days prior to surgery. Neck dissection was 
performed in 38.2% of cases (1).  
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Table 1. Patient demographics and clinical characteristics from the NSQIPA 
  % (N=408)B 
Sex   
Male 60.0 (245) 
Female 40.0 (163) 
Age (years)   
18-44 7.8 (32) 
45-64 43.4 (177) 
65-79 34.6 (141) 
≥80 14.2 (58) 
Race   
Caucasian 83.8 (295) 
Black 10.2 (36) 
Hispanic 2.6 (9) 
Asian 3.4 (12) 
BMI   
<18.5 22.3 (90) 
18.5-24.9 38.6 (156) 
25.0-29.9 33.7 (136) 
≥30.0 5.4 (22) 
ASA classification   
1 2.5 (10) 
2 29.7 (121) 
3 63.7 (260) 
4 4.2 (17) 
                                                        
A Reproduced with permission from: Schwam ZG, Sosa JA, Roman SA, Judson BL. Complications and mortality 
following surgery for oral cavity cancer: analysis of 408 cases. Laryngoscope 2015;125:1869-73. 
B Numbers may not add to total due to missing data 
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Diabetes 11.8 (48) 
Current smoker 32.8 (134) 
Heavy alcohol use 9.1 (37) 
Pulmonary comorbidity 15.7 (64) 
Cardiovascular 
comorbidity 
11.5 (47) 
Hypertension 52.5 (214) 
Prior stroke/TIA 8.3 (34) 
Neoadjuvant 
chemotherapy 
1.0 (4) 
Neoadjuvant XRT 2.0 (8) 
Chronic steroids 3.2 (13) 
Coagulopathy 2.7 (11) 
Poor functional status 4.2 (17) 
Significant weight loss 
prior to surgery 
6.6 (27) 
Operation within prior 
30 days 
3.0 (12) 
Abbreviations: NSQIP=National Surgical Quality Improvement Program, BMI=body mass index, 
ASA=American Society of Anesthesiologists, TIA=transient ischemic attack, XRT=radiotherapy 
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30-day postoperative complications and adverse events 
The overall thirty-day complication rate was 20.3%, and four patients (1.0%) died within 
30 days of surgery (Table 2). The most common adverse events were reoperation as well 
as infectious, respiratory, and surgical-site complications.  Graft failure, venous 
thromboembolism, cardiovascular, and renal complications occurred infrequently. 
Unfortunately, detailed information regarding the type of graft (split-thickness skin graft 
versus pedicle or free flap) was not available in the database. The majority of 
complications occurred between postoperative day (POD) two and ten, although most 
venous thromboembolic events and renal insufficiency occurred much later (median 22.0 
and 22.5 days, respectively) (1).   
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Table 2. Complications and adverse events within 30 days of surgeryA 
  % (n)B 
Overall 20.3 (83) 
Reoperation 9.6 (39) 
Infectious 6.6 (27) 
Respiratory 5.1 (21) 
Surgical-site 4.7 (19) 
Flap failure 2.2 (9) 
VTE 1.7 (7) 
Cardiovascular 1.5 (6) 
Renal 1.2 (5) 
Death 1.0 (4) 
Abbreviations: VTE=venous thromboembolism 
 
 
 
 
 
 
 
 
 
                                                        
A Reproduced with permissions from: Schwam ZG, Sosa JA, Roman SA, Judson BL. Complications and mortality 
following surgery for oral cavity cancer: analysis of 408 cases. Laryngoscope 2015;125:1869-73. 
B Numbers do not add to total due to some patients experiencing multiple complications 
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Preoperative risk factors for 30-day postoperative adverse events 
 While several preoperative variables were identified as risk factors for 
experiencing an adverse event postoperatively, some were linked to a variety of 
complications in multivariable analysis (Table 3).  Being a smoker within the year prior 
to surgery was associated with surgical-site and respiratory complications as well as 
reoperation.  Undergoing neck dissection was associated with graft failure [odds ratio 
[OR] 16.97, 95% confidence interval [CI] 1.78-161.44], surgical-site, infectious, and 
respiratory complications, and was associated with an adverse event of any type in 
univariate analysis (32.7% versus 12.7%, p<.001). Poor functional status predisposed 
patients to infectious and respiratory events, and steroid use for a chronic condition was 
the only risk factor for thirty-day mortality (OR 56.44, 95% CI 2.03-1569.28].  There 
were no independent risk factors identified for cardiovascular or renal complications (1).    
 
Length-of-stay and post-discharge complications 
 The median and mean length-of-stay were found to be 3.0 and 4.8 days, 
respectively. Patients who experienced an in-hospital adverse event had a significantly 
longer inpatient admission (mean 14.8 versus 3.1 days, p<.001). While most adverse 
events occurred within the hospital, twenty patients (4.9%) experienced 17.3% of all 
complications in the post-discharge time period.  A significant proportion of surgical-site 
complications (42.1%), sepsis (20.0%), flap failure (22.2%), deep venous thrombosis 
(33.3%), and death (25.0%) occurred after admission.  While the vast majority (91.3%) of 
post-discharge complications occurred by post-discharge day 14, 52% of post-discharge 
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wound dehiscences and 67% of surgical site infections occurred by post-discharge day 7 
(1). 
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Table 3. Independent risk factors for postoperative eventsA  
Abbreviations: OR=odds ratio, CI=confidence interval, NS=not significant, VTE=venous thromboembolism, Hx=history of, TIA=transient ischemic attack, 
ND=neck dissection 
 
                                                        
A Reproduced with permissions from: Schwam ZG, Sosa JA, Roman SA, Judson BL. Complications and mortality following surgery for oral cavity cancer: analysis of 408 cases. 
Laryngoscope 2015;125:1869-73. 
 
 
Surgical site Infectious VTE Respiratory Reoperation 
Risk Factor OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p 
Black 3.89 (1.11-13.66) .034  NS  NS  NS  NS 
Current smoker 5.13 (1.67-15.76) .004  NS  NS 3.59 (1.39-9.29) .008 3.07 (1.53-6.13) .002 
Significant weight 
loss 
4.59 (1.05-20.09) .043  NS  NS   3.19 (1.19-8.54) .021 
Poor functional 
status 
 NS 6.73 (1.51-30.03) .013  NS 5.57 (1.21-25.53) .027  NS 
chronic steroid use  NS  NS 12.96 (1.99-84.47) .007  NS  NS 
Operation in prior 
30 days 
 NS  NS 14.31 (2.18-93.83) .006  NS  NS 
Hx stroke/TIA  NS  NS  NS 3.41 (1.03-11.26) .044 3.68 (1.46-9.29) .006 
ND 6.30 (1.84-21.57) .003 3.83 (1.59-9.24) .003  NS 6.17 (2.07-18.35) .001  NS 
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Changes in patient demographics, clinical characteristics, and survival by year of 
diagnosis in the NCDB  
 After applying the several inclusion and exclusion criteria to patient records from 
the NCDB, 13,655 patient records were available for analysis. Patients were divided into 
two cohorts based on year of diagnosis: those diagnosed 1998-2003 (n=7,734) and those 
diagnosed in 2004-2006 (n=5,921). The overall median follow-up time was 43.6 months 
(range 0.0-176.2 months), while the median follow-up times for those diagnosed 1998-
2003 and 2004-2006 were 33.9 months (range 0.0-176.2 months) and 55.1 months (0.0-
106.9 months), respectively (2).  
 
 Patients diagnosed in the later cohort were younger, more often had private 
insurance, and received their care in academic/research facilities and high volume centers 
(Table 4).  Patients diagnosed in 2004-2006 also had a higher proportion of T≤2 lesions, 
N0 nodal disease, and early stage disease (Stages I and II). Negative surgical margins, 
neck dissections, and adjuvant chemoradiotherapy were more often administered to 
patients diagnosed in 2004-2006 (2).  
 
 Observed three-year overall survival improved significantly from 1998 to 2006 
(21.7% to 50.9%, p<.001).  Patients diagnosed from 2004-2006 were found to have a 
median estimated survival of 88.2 months (95% CI 84.2-92.2 months), compared to 52.2 
months (95% CI 49.6-54.7 months) in univariate Kaplan-Meier analysis (Figure 1) (2).   
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Table 4. Patient demographics and facility data stratified by year of diagnosisB 
 1998-2003 2004-2006  
 % (n=7,734) % (n=5,921) p 
Sex    
Male 62.6 61.3 
.131 
Female 37.4 38.7 
Age (years)    
18-64 50.8 56.4 
<.001 
≥65 49.2 43.6 
Race    
White 88.0 88.3 
<.001 
Black 6.0 4.3 
Hispanic 2.1 3.0 
Asian 3.4 3.7 
Other 0.6 0.7 
Insurance    
Private 40.5 45.0 
<.001 
Uninsured/Medicaid 11.9 12.3 
Medicare/other 
government 
47.5 42.6 
Facility Type    
ARP 42.4 51.7 
<.001 
Non-ARP 57.6 48.3 
Facility Volume    
Low 54.9 45.7 <.001 
                                                        
B Reproduced with permissions from Schwam ZG, Judson BL. Improved prognosis for patients with oral cavity 
squamous cell carcinoma: analysis of the National Cancer Database 1998-2006. Oral Oncol 2016;52:45-51. 
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High 45.1 54.3 
T-classification    
1 42.1 45.2 
<.001 
2 32.2 32.1 
3 10.1 7.2 
4 15.6 15.5 
N-classification    
0 78.2 79.6 
.006 
1 10.7 9.1 
2 10.4 10.8 
3 0.7 0.5 
M-classification    
0 99.6 99.6 
.846 
1 0.4 0.4 
Overall Stage    
I 39.4 42.4 
<.001 
II 24.7 25.0 
III 13.5 10.7 
IV 22.4 21.9 
Treatment Regimen    
Surgery alone 64.8 66.9 
<.001 Surgery + RT 29.7 21.6 
Surgery + CRT 5.4 11.5 
Surgical Margins    
Negative 85.8 88.2 
<.001 
Positive 14.2 11.8 
Neck Dissection    
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No 49.6 47.2 
.006 
Yes 50.4 52.8 
Abbreviations: ARP-Academic/Research Program, RT-Radiation Therapy, CRT-
Chemoradiation Therapy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
31 
Figure 1. Overall survival of all patients stratified by year of diagnosisB 
 
 
 
 
 
 
 
 
 
                                                        
B Reproduced with permissions from Schwam ZG, Judson BL. Improved prognosis for patients with oral cavity 
squamous cell carcinoma: analysis of the National Cancer Database 1998-2006. Oral Oncol 2016;52:45-51. 
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Changes in treatment patterns and survival by year of diagnosis and disease stage 
 Patients were characterized as having early or late stage (Stages III and IV) 
disease, with the proportion of patients being diagnosed with early stage disease 
increasing from 64.1% to 67.4% between the two time-based cohorts (p<.001). Patients 
presenting with late stage disease were significantly different from early stage patients in 
terms of demographics and several treatment variables; patients with later stage disease 
were more frequently <65 years of age (57.8% versus 50.9%), uninsured/Medicaid 
(18.8% versus 8.6%), non-white (17.3% versus 9.0%), and received their treatment in 
high volume centers (59.0% versus 43.9%) (all p<.001) (2). 
 
 Treatment patterns for patients with early stage disease remained stable between 
1998 and 2006 (Figure 2a); there was a 3.8% increase in the administration of adjuvant 
chemoradiotherapy, and a 1.9% decrease in the administration of adjuvant radiotherapy. 
Surgery followed by adjuvant radiotherapy had a negative temporal correlation with 
three-year overall survival (Pearson coefficient -0.77, p=.016), whereas adjuvant 
chemoradiotherapy was positively correlated with three-year overall survival (Pearson 
coefficient 0.88, p=.002). There was a significant improvement for patients with early 
stage disease in three-year overall survival from 23.5% to 59.7% over the study period 
(p<.001) (2).  
 
 Early stage disease patients diagnosed in 1998-2003 had higher rates of positive 
margins (11.0% versus 8.3%), treatment in a low volume center (61.1% versus 50.0%), 
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and age ≥65 years (52.1% versus 45.4%) (all p<.001). Neck dissections increased from 
22.8% to 37.6% over the study period (p<.001) (2).  
 
Patients with late stage disease saw a similar improvement in three-year overall 
survival from 17.9% to 33.9% over the study period (Figure 2b). A strong, positive 
temporal correlation was found between administration of adjuvant chemoradiotherapy, 
which increased from 8.3% to 36.4%, and three-year overall survival (Pearson coefficient 
0.92, p<.001). Receipt of adjuvant radiotherapy was observed to fall from 54.0% to 
31.4%, and was negatively associated with survival (Pearson coefficient=-0.95, p<.001) 
(2).  
 
Late stage disease patients diagnosed from 2004 to 2006 were more often <65 
years old (60.2% versus 56.0%, p=.004), more commonly had private insurance (40.9% 
versus 37.5%, p=.008), received treatment in a high volume facility (63.1% versus 56.1%, 
p<.001), and presented with Stage IV disease (67.0% versus 62.4%, p=.001).  No 
statistical difference was found in surgical margin status between the two periods 
(p=.341) (2).    
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Figure 2a. Temporal trends in treatment and three-year overall survival among patients 
with early stage diseaseB 
 
Abbreviations: RT-radiation therapy, CRT-chemoradiation therapy, OS-overall survival 
 
 
 
 
 
 
 
 
 
                                                        
B Reproduced with permission from Schwam ZG, Judson BL. Improved prognosis for patients with oral cavity 
squamous cell carcinoma: analysis of the National Cancer Database 1998-2006. Oral Oncol 2016;52:45-51. 
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Figure 2b. Temporal trends in treatment and three-year overall survival among patients 
with late stage diseaseB 
 
Abbreviations: RT-radiation therapy, CRT-chemoradiation therapy, OS-overall survival 
 
 
 
 
 
 
 
 
 
                                                        
B Reproduced with permission from Schwam ZG, Judson BL. Improved prognosis for patients with oral cavity 
squamous cell carcinoma: analysis of the National Cancer Database 1998-2006. Oral Oncol 2016;52:45-51. 
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Long-term prognostic factors in multivariable analysis 
  Several independent risk factors for mortality were identified in multivariable 
analysis.  Older age, insurance status, year of diagnosis, later stage at diagnosis, 
administration of adjuvant chemoradiotherapy, and the presence of positive margins were 
all associated with increased mortality in early and late stage disease patients, but also 
when these two disease-based cohorts were combined (Table 5).  Receiving treatment in 
a high volume facility and undergoing neck dissection were associated with better overall 
survival in early stage disease patients and when all patients were combined, but not in 
late stage disease patients.  Being treated in an academic/research program was linked to 
improved prognosis when all patients were combined, but not for a particular staging 
group.  Compared to surgery alone, receiving adjuvant radiotherapy was associated with 
greater risk of death in early stage disease patients and when all patients were combined. 
The year of diagnosis was associated with improved overall survival (Hazard ratio [HR] 
0.76, 95% CI 0.72-0.80) in multivariable models, and those diagnosed 2004-2006 had a 
significantly higher three-year overall survival rate as compared to those diagnosed in the 
earlier cohort (48.4% versus 29.2%, p<.001) (2).    
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Table 5. Independent risk factors for mortality stratified by disease-stateB 
 Early Stage (I, II) Late Stage (III, IV) All Stages (I-IV) 
 HR (95% CI) p HR (95% CI) p HR (95% CI) p 
Sex       
Male (Ref) 1.00  1.00  1.00  
Female 1.00 (0.93-1.07) .943 0.92 (0.85-0.99) .020 0.95 (0.91-1.01) .062 
Age (years)       
18-64 (Ref) 1.00  1.00  1.00  
≥65 1.80 (1.62-1.99) <.001 1.41 (1.26-1.58) <.001 1.59 (1.48-1.72) <.001 
Race       
White (Ref) 1.00  1.00  1.00  
Black 1.43 (1.21-1.69) <.001 0.99 (0.87-1.12) .866 1.10 (0.99-1.21) .078 
Hispanic 1.00 (0.79-1.69) .998 0.85 (0.66-1.08) .173 0.91 (0.77-1.08) .271 
Asian 0.71 (0.57-0.89) .003 0.85 (0.70-1.02) .075 0.78 (0.68-0.90) .001 
Other 0.96 (0.59-1.54) .859 0.87 (0.57-1.32) .503 0.88 (0.64-1.21) .444 
Insurance       
Private (Ref) 1.00  1.00  1.00  
Uninsured/Medicaid 1.54 (1.35-1.76) <.001 1.34 (1.32-1.49) <.001 1.52 (1.40-1.64) <.001 
Medicare/other 
government 
1.58 (1.43-1.76) <.001 1.29 (1.15-1.44) <.001 1.45 (1.35-1.57) <.001 
Facility Type       
ARP (Ref) 1.00  1.00  1.00  
Non-ARP 1.05 (0.97-1.15) .121 1.08 (0.98-1.18) .123 1.07 (1.01-1.14) .030 
Facility Volume       
Low (Ref) 1.00  1.00  1.00  
                                                        
B Reproduced with permission from Schwam ZG, Judson BL. Improved prognosis for patients with oral cavity 
squamous cell carcinoma: analysis of the National Cancer Database 1998-2006. Oral Oncol 2016;52:45-51. 
 
  
38 
High 0.84 (0.79-0.90) <.001 0.97 (0.88-1.06) .470 0.91 (0.85-0.97) .002 
Year of Diagnosis       
1998-2003 (Ref) 1.00  1.00  1.00  
2004-2006 0.67 (0.63-0.72) <.001 0.87 (0.81-0.94) <.001 0.76 (0.72-0.80) <.001 
Stage       
I (Ref) 1.00  -- -- 1.00  
II 1.49 (1.39-1.60) <.001 -- -- 1.49 (1.40-1.60) <.001 
III (Ref) -- -- 1.00  1.96 (1.80-2.14) <.001 
IV -- -- 1.22 (1.13-1.32) <.001 2.44 (2.26-2.64) <.001 
Treatment Regimen       
Surgery (Ref) 1.00  1.00  1.00  
Surgery + RT 1.39 (1.38-1.51) <.001 1.00 (0.92-1.08) .999 1.18 (1.11-1.25) <.001 
Surgery + CRT 1.80 (1.48-2.18) <.001 1.13 (1.02-1.26) .021 1.41 (1.29-1.54) <.001 
Neck Dissection       
No (Ref) 1.00  1.00  1.00  
Yes 0.80 (0.75-0.87) <.001 1.00 (0.91-1.11) .952 0.90 (0.84-0.95) <.001 
Surgical Margins       
Negative (Ref) 1.00  1.00  1.00  
Positive 1.39 (1.26-1.53) <.001 1.55 (1.43-1.69) <.001 1.50 (1.41-1.60) <.001 
Abbreviations: HR-Hazard Ratio, CI-Confidence interval, Ref-Referent category, ARP-
Academic/Research Program, RT-Radiation Therapy, CRT-Chemoradiation Therapy 
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Factors associated with receipt of adjuvant therapies 
 When all patients were combined, 65.7% received surgery alone, 29.1% received 
adjuvant radiotherapy, and 8.1% received adjuvant chemoradiotherapy.  In univariate 
analysis, later year of diagnosis, younger age, black race, private insurance, getting 
treated in an academic program or high volume facility, T4 lesions, higher overall stage, 
positive margins, and undergoing neck dissection were all associated with the receipt of 
adjuvant chemoradiotherapy (Table 6) (2).  
  
 Nearly one in six patients receiving adjuvant chemoradiotherapy did not undergo 
neck dissection, and 76.1% had negative surgical margins. Data regarding dose of 
radiotherapy were scant, being present for only 21.1% of our cohort. In those patients for 
whom data were available, the median dose was 56.0 Gray (Gy), and 18.2% received 
doses between 60.0 and 66.0 Gy.  The median dose increased over the study period from 
52.0 Gy (1998-2003) to 59.4 Gy (2004-2006). No data were available regarding type, 
dose, or adequacy of chemotherapeutic agents (2).  
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Table 6. Unadjusted risk factors for administration of adjuvant therapiesB 
 Surgery alone Surgery + RT Surgery + CRT p 
 % (n=8,979) % (n=3,974) % (n=1,102)  
Year of Diagnosis     
1998-2003 55.9 64.3 38.2 
<.001 
2004-2006 44.1 35.7 61.8 
Sex     
Male 60.9 63.5 66.4 
.001 
Female 39.1 36.5 33.6 
Age (years)     
18-64 48.6 57.8 76.1 
<.001 
≥65 51.4 42.2 23.9 
Race     
White 90.6 84.4 79.9 
<.001 
Black 3.5 8.1 10.0 
Hispanic 2.1 2.9 3.9 
Asian 3.2 3.9 5.2 
Other 0.6 0.6 1.0 
Insurance     
Private 40.9 42.8 54.3 
<.001 
Uninsured/Medicaid 10.0 15.2 19.7 
Medicare/other 
government 
49.1 42.0 26.0 
Facility Type     
ARP 44.1 48.9 57.7 <.001 
                                                        
B Reproduced with permission from Schwam ZG, Judson BL. Improved prognosis for patients with oral cavity 
squamous cell carcinoma: analysis of the National Cancer Database 1998-2006. Oral Oncol 2016;52:45-51.  
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Non-ARP 55.9 51.1 42.3 
Facility Volume     
Low 51.5 51.9 42.6 
<.001 
High 48.5 48.1 57.4 
T-classification     
1 56.7 19.7 12.6 
<.001 
2 29.2 39.3 32.6 
3 5.3 14.6 18.7 
4 8.8 26.4 35.1 
N-classification     
0 90.1 62.9 38.5 
<.001 
1 5.5 17.9 21.2 
2 4.1 18.6 37.3 
3 0.2 0.7 3.0 
M-classification     
0 99.7 99.6 99.1 
.003 
1 0.3 0.4 0.9 
Overall Stage     
I 55.2 15.2 5.8 
<.001 
II 25.4 26.5 14.4 
III 7.9 20.6 20.9 
IV 11.4 37.7 58.9 
Surgical Margins     
Negative 92.2 76.8 76.1 
<.001 
Positive 7.8 23.2 23.9 
Neck Dissection     
No 60.0 30.0 15.9 <.001 
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Yes 40.0 70.0 84.1 
 
Abbreviations: RT-radiation therapy, CRT-chemoradiation therapy, ARP-
Academic/Research Program 
 
Discussion 
 There is a scarcity of multi-institutional level data characterizing the postoperative 
complications following oral cavity cancer surgery, the risk factors for them, and the 
time-course over which they occur (1).  While changes in prognosis have been reported 
in oral cancer in international cohorts (81), there is a similar lack of multi-institutional 
data from the United States (2).    
 
 In measuring thirty-day morbidity and mortality following primary resection for 
oral cavity cancer, the overall complication rate was 20.3% and mortality occurred in 
1.0% of patients.  In their comparison of clinical registry and administrative data from 
355 oral cavity cancer patients treated at Memorial Sloan-Kettering Cancer Center, Awad 
et al. found that all major complications, one-third of total complications, and 27% of 
patients were found in the NSQIP, in comparison to their own administrative records (90).  
They found a significantly higher overall adverse rate of 62.0%, but were also able to 
track many procedure-specific complications including orocutaneous fistula, trismus, and 
chyle leak that are not found in the NSQIP.  Awad et al. tracked only complications 
occurring during admission, and stopped tracking them after 45 days (1).  
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Awad’s group found that 34% of patients undergoing neck dissection experienced 
a complication (90), while we measured a very similar value of 33%. The rate of 
complications after neck dissection ranges in the literature between 7-16% for major 
complications and up to 38% in total (110,111,112,113,114), although pre-neck 
dissection therapy such as radiation, chemotherapy, or prior surgery must be taken into 
consideration in addition to extent of neck dissection.  In one prospective trial of elective 
modified radical (MRND) versus supraomohyoid (SOH) neck dissection for T2-T4 oral 
cavity malignancies, the MRND group had a significantly higher complication rate (41% 
versus 25%, p=.043) and a longer median length of stay (9 days versus 7 days) when 
compared to the SOH group (115). In our study, we found that undergoing neck 
dissection was a risk factor for several postoperative complications, including surgical-
site, infectious, and respiratory complications.  While the neck dissection itself may 
increase the likelihood of complications by prolonging operative times, extending 
incisions, and putting critical neurovascular structures at risk, we believe it to be a proxy 
variable for more advanced disease (37) in the NSQIP, which does not track oncologic 
variables such as TNM classifications or overall stage of disease (1).  
 
We found that the rate of neck dissections increased significantly between 1998 
and 2006, particularly for patients with early stage disease. It was also noted that 
undergoing neck dissection was associated with better overall survival in early stage 
disease patients and when all patients were combined (2). A recent randomized control 
trial from Tata Memorial Centre evaluated the role of elective versus therapeutic neck 
dissection in 596 patients with T≤2, clinically N0 lateralized oral cancers (47).  The 
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investigators found several benefits to elective node dissection, including significantly 
fewer recurrences, a three-year overall survival rate of 80.0% compared to 67.5%, a 
hazard ratio for mortality of 0.64 (95% CI 0.45-0.92), and a significantly higher rate of 
three-year disease-free survival (69.5% versus 45.9%).  Adverse event rates were 
relatively low, with 6.6% of the elective group and 3.6% of the therapeutic group having 
complications.  
 
In addition to neck dissection as a significant risk factor for multiple 
complications, we found that cigarette smoking within the year prior to surgery and 
weight loss ≥10% within the six months prior to surgery were associated with surgical-
site complications. Perioperative smoking cessation is frequently recommended due to its 
known association with impaired wound healing (116,117,118) and surgical site 
infections (1,119,120).  Weight loss resulting in physiologic impairments has been 
associated with postoperative septic complications (1,121).  In our study, we believe that 
significant weight loss most likely reflects cancer-induced inflammation as well as 
difficulties with eating as a result of the lesion’s location in the oral cavity (1).  
Furthermore, it has been shown that systemic inflammation and weight loss affect 
albumin concentration (122,123), which was associated with wound complications in a 
NSQIP study of over two thousand patients undergoing laryngectomy (1,124).   
 
Minimizing readmission after surgery has become a quality of care initiative 
(125), especially in light of its ability to influence Medicare reimbursements (126).  
While the NSQIP does not track readmission rates, Luryi et al. found a 3.5% readmission 
  
45 
rate following surgery for oral cancers (87) using the National Cancer Database.  In the 
same study, neck dissection, male gender, and T3 tumor classification were associated 
with unplanned readmission.  In our cohort, we measured thirty-day reoperation 
occurring in 9.6% of patients, with risk factors including cigarette smoking, recent weight 
loss, and history of stroke/TIA.  As these very same risk factors were also noted to be 
associated with surgical-site and respiratory complications, reoperation may have been to 
create or revise a tracheostomy stoma.  Cigarette smoking in the two weeks prior to 
surgery has also been linked to major flap complications requiring return to the operating 
room (127), and may explain some of the reoperations in our study (1).  
 
Post-discharge complications are a huge source of hospital readmissions, with 
nearly one in seven surgical patients experiencing a preventable adverse event leading to 
unintended readmission (105,128).  In our study, we found that 4.9% of patients 
experienced 17.3% of all complications after leaving the hospital, and that over 90% of 
them occurred within 14 days of discharge.  Many superficial wound infections and much 
of the dehiscence occur within 7 days of discharge, however.  This compares favorably to 
the NSQIP analysis of 21 groups of general surgery procedures by Kazaure and 
colleagues, in which 41.5% of all complications occurred in the post-discharge timeframe 
(105).  In using the NSQIP to examine over 48,000 patients undergoing a diverse range 
of otolaryngologic procedures, Chen et al. had similar findings, showing that about three-
quarters of post-discharge complications occurred by post-discharge day 14, with many 
of them concerning the surgical-site or systemic infections (1,88). 
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In order to maximize short-term well-being and to minimize healthcare spending 
on unintended readmissions, the literature shows that early clinical follow-up is essential 
(1).  It has been reported that half of patients readmitted for post-discharge complications 
had not seen a physician within the month after discharge (128).  Using the Surveillance, 
Epidemiology, and End Results (SEER) database, Tuggle et al. showed that seeing a 
healthcare provider in the 30 days after surgery could reduce re-hospitalization rates by 
55% (absolute decrease of 6.3%) in elderly patients undergoing thyroidectomy (129).  
Similarly, Robles was able to show that hiring a nurse practitioner in a surgical practice 
not only increased telephone communication and therapy services, but also reduced 
unnecessary emergency room visits by 48% (absolute reduction of 12%) (130). As many 
of the post-discharge complications occurred within the one to two weeks after leaving 
the hospital, early intervention would likely play an important role in minimizing 
morbidity and unnecessary healthcare spending (1).  
 
Our data from the National Cancer Database demonstrate a large increase in 
three-year overall survival for patients with oral cavity squamous cell carcinomas using 
multi-institutional data from hundreds of participating centers throughout the United 
States.  In a 20-year retrospective study of 2,738 oral cavity cancer patients from seven 
leading international cancer centers, Amit et al. found an 11% improvement in five-year 
overall survival and a 12% increase in disease-specific survival when all patients were 
examined together (81).  Surgery alone was performed in 31% of their cohort, adjuvant 
radiotherapy was administered in 51%, and adjuvant chemoradiotherapy in 18%. 
Additionally, 60% of patients underwent elective neck dissection, and 40% received 
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therapeutic neck dissection. When splitting the study population into two time-of-
diagnosis based cohorts (1990-2000 and 2001-2011), the authors found that the later 
cohort presented at an earlier age, with more advanced disease and extracapsular 
extension, and more often had negative margins.  A limited, selective neck dissection was 
also more frequently performed in the later group.  The decade of diagnosis was an 
important predictor of survival, with patients diagnosed 2001-2011 having better overall, 
disease-specific, and disease-free survival in multivariate analyses.  In a study by Pulte et 
al. using the SEER database to examine trends in prognosis of head and neck cancers, the 
investigators similarly found a 14.4% increase in overall survival for patients with lesions 
of the oral tongue between 1992-1996 and 2002-2006 (131). We found a much larger 
improvement in overall survival than found in the Amit and Pulte studies, which may be 
due to either changes in patterns of follow-up by the NCDB or heterogeneity of the 
participating sites; the NCDB includes hospital registry data from over 1500 participating 
sites (97), while Amit and colleagues tracked patients only from seven leading cancer 
hospitals throughout the world. We found period of diagnosis to be associated with 
improved overall survival, and found that those presenting later more often were younger 
and had early stage disease; this may be explained by greater access to healthcare, more 
effective disease screening, or increased awareness (2).  
 
Receiving treatment in a high-volume center took place more often in 2004-2006, 
and was associated with improved overall survival in patients with early stage disease 
and when all patients were analyzed together.  This was closely mirrored by an increase 
in patients receiving care in academic/research programs.  These changes in treatment 
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setting may be from some degree of regionalization of cancer care, shifts in referral 
patterns, or more physicians going to work for larger hospital systems (2).  Facility 
volume has been shown to be a positive factor in head and neck cancer prognostication 
using multiple databases (133,134) and government registries (135,136).  Surgical 
resection of the primary tumor is often the first therapeutic step in the treatment of oral 
cavity malignancies (37), and higher-volume centers may be more facile with larger 
ablative procedures requiring free tissue transfer as part of the reconstruction.  Higher 
volume centers may also have a more formal way of approaching oncologic treatment 
decision making in the way of tumor boards, which have been shown to intensify 
proposed head and neck cancer treatment and up-stage disease (2,136).  We found that 
nearly 80% of high volume facilities were academic/research programs, which have been 
largely superior to non-academic facilities in terms of process measures and risk-adjusted 
mortality for complex patients in the literature (137).  We labeled a facility “high volume” 
if it was in the ≥90th percentile, and did not determine the minimum percentile for which 
there was a survival benefit (2).  
 
In addition to treatment in a high volume facility, this study found positive 
surgical margins to be a poor prognostic factor for patients with oral cavity squamous cell 
carcinoma.  Positive margins are more commonly found in the oral cavity when 
compared to other head and neck sub-sites (138), are an important determinant in the 
decision to administer adjuvant treatment (37), and put patients at higher risk of disease 
recurrence and compromised disease-specific survival (2,139).  We found a significant 
decrease in the rate of patients with positive margins and a steady increase in patients 
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receiving adjuvant therapy; this is likely due to high-risk pathologic features not 
accounted for in the database, such as extracapsular spread and perineural invasion.  In 
using the NCDB to examine over 20,000 early stage oral cavity cancer patients, Luryi et 
al. observed positive margins in 7.5% of the study population, with a range of 0.0-43.8% 
(140).  The authors found that more advanced disease and receiving treatment in a lower 
volume or non-academic facility to be risk factors for positive surgical margins. While 
we did not examine risk factors for positive margins, we did see a corresponding decrease 
in both presentation with late stage disease and treatment in low volume/non-academic 
facilities to accompany the decrease in rate of positive margins (2).  
 
  Receipt of adjuvant chemoradiotherapy was associated with worse overall 
survival in all patients, regardless of disease stage.  This is in contrast to its strong, 
positive temporal correlation with three-year overall survival in late stage patients.  
Administration of adjuvant chemoradiotherapy became increasingly popular after the 
publication of two noteworthy trials, RTOG 9501 (66) and EORTC 22931 (67), which 
compared the efficacy of adjuvant chemoradiotherapy to adjuvant radiotherapy in high-
risk and late stage head and neck cancer, respectively.  Both studies reported superior 
locoregional control and a more serious toxicity profile in the chemoradiotherapy group.  
The two trials differed slightly with respect to survival analyses; RTOG 9501 reported 
that chemoradiotherapy was associated with improved disease-free survival, but not 
overall survival, while EORTC 22931 demonstrated better progression-free and overall 
survival in the chemoradiotherapy group. When the authors pooled their data in a follow-
up analysis, they concluded that adjuvant chemoradiotherapy was best suited for those 
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with extracapsular extension or positive margins (2,65).  In our cohort, nearly one in six 
patients receiving adjuvant chemoradiotherapy did not undergo neck dissection, and over 
three-quarters receiving such therapy had negative margins.  Additionally, many patients 
with positive margins did not receive adjuvant therapy. While we were unable to account 
for certain high-risk pathologic features that are currently indications for adjuvant 
treatment, the appropriateness of certain treatment regimens must be called into question 
(2). Unfortunately, the reason for non-administration of therapy was lacking for the 
majority of patients, and could not be analyzed in a meaningful way.  It is possible that 
patients had significant comorbidities precluding them from receiving treatment, or that 
they refused recommended therapy.  The majority of patients were also diagnosed and 
treated prior to the publication of those two trials. In analyzing the adequacy of 
radiotherapy, we found that the median regional dose to be 56.0 Gy, with only 18.2% of 
patients for whom there was data receiving doses in line with the trial protocols. 
Adequacy of chemotherapy or systemic therapies was not possible to measure in the 
database, and toxicity from adjuvant therapy as a cause for mortality cannot be excluded 
(2).  
 
Several additional limitations must be taken into account when analyzing the 
results of our data concerning both short- and long-term prognosis of oral cavity 
malignancies.  In terms of thirty-day morbidity and mortality, many complications of 
interest may not be tracked in the NSQIP, potentially underestimating the true 
complication rate.  Patients in our cohort also underwent a variety of concurrent 
procedures, from free flaps to parotidectomies, with each procedure having a different 
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adverse event profile.  Furthermore, the NSQIP does not keep track of oncologic 
variables, hospital or surgeon volume, prior surgery, or rationale/timing of reoperation (1).  
Several other variables were not adjusted for, and may impact our results: including 
trainee involvement, length of procedure, surgeon skill, postoperative nursing care, and 
patient compliance with prescribed regimens. While we were able to give a timecourse 
over which complications occurred, there is wide variation in admission and discharge  
practices amongst facilities.  An important variable not recorded in the NSQIP is time 
from hospital discharge to outpatient follow-up, as this may be an important avenue for 
intervention. Additionally, some complications in the NSQIP may not be as specific as 
desired; for example, return to the operating room is listed, but without cause. Returning 
because of postoperative hemorrhage and returning to obtain negative margins are very 
different events.  Additionally, we selected a cohort in which data for the variables of 
interest were present, introducing potential bias, unless one assumes that data is missed at 
random.  While the NSQIP collects data from its hundreds of participating sites, entry 
requirements including a large subscription fee and the cost of employing a SCNR; this 
may be prohibitive for smaller facilities or may skew the dataset to representing 
institutions with a strong desire to study and improve outcomes.  
 
In analyzing changes in long-term prognosis, we were unable to analyze Charlson 
comorbidity scores, relative timing of adjuvant treatment, and a host of high-risk 
pathologic features that are associated with worse prognosis in oral cancers.  The NCDB 
also limits analysis to overall survival, as cause of death is not available. Individual 
patient income and level of education are not available, which may impact treatment 
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decisions. Undergoing neck dissection was not one of our inclusion criteria, which may 
have led to under-staging for certain patients.  We limited our analysis to patients 
diagnosed between 1998 and 2006 due to data availability; if extended in either direction, 
a more pronounced change in prognosis may have been observed (2).  Additionally, the 
NCDB has additional limitations that should further inform the results of our study.  As it 
currently stands, only CoC-approved cancer centers are allowed to report their results to 
the NCDB (141,142); criteria for CoC-approval include having a wide range of oncologic 
services and specialists, and must participate in several quality-improvement activities 
(141). CoC-approved hospitals have been found to be more likely associated with 
residency programs and medical schools, more frequently accredited by the Joint 
Commission, less frequently in rural areas, and tend to have higher volume surgical 
facilities and more comprehensive oncologic services (141). As the vast majority of 
facilities are not CoC-accredited (142), the NCDB may represent an unrepresentative 
cross-section of oral cancer care nationwide.       
 
Conclusions  
 In examining a multicenter cohort of patients with oral cavity cancer, we 
determined that a significant number of patients undergoing primary resection experience 
a postoperative adverse event, and determined that a small yet significant minority 
experience complications after admission. We identified risk factors that may serve as 
potential red flags in the patient history for postoperative complications. Furthermore, we 
identified the two weeks after discharge as a high-risk time for vulnerable patients, and 
believe that early clinical follow-up may mitigate the morbidity associated with post-
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discharge complications and prevent costly readmission in high-risk patients (1).  
Monitoring our advancements in treatment of oncologic disease is an important task to 
undertake, and can be done through examining changes in prognosis for a given disease. 
This was the first study showing that the long-term prognosis for patients with oral cavity 
squamous cell carcinoma has improved significantly for both early and late stage disease 
patients using a nationwide cohort.  Similar changes in prognosis have only been 
demonstrated in patients with human papillomavirus-positive oropharyngeal squamous 
cell carcinoma. This study was the first to show that receipt of adjuvant 
chemoradiotherapy has increased substantially in the treatment of oral cavity squamous 
cell carcinoma, yet we also found it to be associated with compromised overall survival.  
We think this represents a selection bias where patients with high-risk pathologic features 
not accounted for in the NCDB were more likely to receive such therapy.  We believe 
that further work is needed in the way of clinical trials to determine the efficacy of 
adjuvant therapies specifically in patients with oral cavity squamous cell carcinoma (2).     
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